Amphastar Pharma (AMPH) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2019
November 7, 2019 4:06 PM ESTReports Net Revenues of $80.1 Million for the Three Months Ended September 30, 2019
RANCHO CUCAMONGA, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (Amphastar or the Company) today reported results for the three months ended September 30, 2019.
Third Quarter Highlights
Net revenues of $80.1 million for the third quarterGAAP net income of $1.3 million, or $0.03 per share, for the third quarterAdjusted non-GAAP net income of $5.2 million, or $0.10 per share, for the third quarterDr. Jack Zhang, Amphastars Chief Executive Officer, commented: A significant accomplishment... More
